Noom Med bundles medication with structured behavioral coaching; Hims bundles medication with a broader health-services ecosystem and a separate membership fee. Neither is medication-focused in the way a dedicated GLP-1 clinic is.
Luma Health's semaglutide ($197/month) and tirzepatide ($297/month) skip both bundles for a single flat price.
Noom Med and Hims approach GLP-1 treatment from different starting points — Noom from behavioral psychology, Hims from broad consumer telehealth — but both add a layer of cost beyond the medication itself. Here's how they actually compare.
Pricing Comparison
Noom Med's combined medication-and-coaching pricing has been reported at $199-$399+/month, with no option to access just the medication separately. Hims charges a distinct membership fee ($39 first month, then $149/month) plus medication cost billed separately, for a combined minimum around $298/month. Both structures add meaningful cost beyond a medication-only price.
What Each Platform Bundles In
Noom Med's bundle is behavioral: daily coaching content, food psychology lessons, and habit-tracking tools built on its established coaching platform. Hims's bundle is more about broader platform access and consumer-facing polish — provider messaging, its wider health-services ecosystem, and (historically) both compounded and brand-name medication options, though compounded availability has shifted with 2025-2026 regulatory changes.
If your main goal is effective medical treatment without paying for bundled extras, both platforms include cost layers beyond the medication itself — Noom's coaching app, Hims's membership fee. Whether either bundle is worth it depends entirely on whether you'll actually use what's bundled in.
A Regulatory Difference Worth Noting
Hims faced direct regulatory scrutiny in 2025-2026, including an FDA warning letter and a Novo Nordisk lawsuit that led to a settlement shifting Hims toward branded product distribution. Noom Med hasn't faced comparable public regulatory action as of this writing. This doesn't necessarily reflect on either platform's current day-to-day service quality, but it's a data point worth knowing given how much the compounded-GLP-1 landscape has shifted.
Which Fits You Better
- Specifically want structured behavioral coaching content
- Value habit-tracking tools built into your medication program
- Are comfortable with the bundled app premium
- Want medical care without an app or membership-fee layer
- Want the clearest possible single price
- Prefer sourcing transparency amid recent regulatory shifts
No bundle,
just medical care
Compounded semaglutide at $197/month or tirzepatide at $297/month — medical evaluation, provider visits, and shipping all included, no coaching app or membership fee.
Get Started → Or start your free health assessmentFrequently Asked Questions
Both add cost beyond medication — Noom Med's bundled pricing runs $199-$399+/month, while Hims's membership-plus-medication minimum is around $298/month. Specific comparisons depend on dose and current promotional pricing.
Noom Med bundles medication with structured behavioral coaching; Hims bundles it with a broader consumer health platform and separate membership fee, with less emphasis on structured coaching.
Hims faced an FDA warning letter and a Novo Nordisk lawsuit in 2025-2026 related to compounded semaglutide marketing, leading to a settlement. Noom Med hasn't faced comparable public action as of this writing.
No, when both prescribe the same active ingredient (semaglutide or tirzepatide), the clinical mechanism is the same. What differs is bundled features and pricing structure.
Yes. A focused, flat-rate compounded provider prices the medical evaluation and medication as a single number, without an app subscription or separate membership fee.
This varies by individual experience and current staffing at either platform; some reviews of larger platforms note less consistent provider continuity than smaller, more focused practices.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA.gov. 2025. FDA.gov
- Better Business Bureau. Hims & Hers Inc. complaint profile. BBB.org. 2026. BBB.org